Photo of Panagiotis A. Konstantinopoulos,  MD, PhD

Panagiotis A. Konstantinopoulos, MD, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute


panagiotisa_konstantinopoulos@dfci.harvard.edu

Panagiotis A. Konstantinopoulos, MD, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Attending Oncologist, Gynecologic Medical Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

My primary clinical and research focus is epithelial ovarian cancer (EOC), the fifth leading cause of cancer-related mortality in women and the most lethal of all gynecologic tumors. I am using gene expression profiling to identify novel genes involved in malignant transformation and drug resistance, predict the outcome of advanced disease as well as response to novel therapies, and molecularly characterize a variety of EOC histologic subtypes. This involves a combination of data analysis as well as in vitro work with a special focus on elucidating platinum resistance as well as improving EOC prognostication. My translational research efforts in this area have been supported by the Department of Defense Ovarian Cancer Research Program, the American Association of Cancer Research (AACR), as well as the Clinical Investigator Training Program from Harvard Medical School and MIT. As a clinical researcher, I am also involved as a overall principal investigator (PI) in DFHCC-wide clinical trials as well as site PI at DFCI in DFHCC-wide clinical trials.

Publications

Powered by Harvard Catalyst
  • Guillemette S, Serra RW, Peng M, Hayes JA, Konstantinopoulos PA, Green MR, Cantor SB. Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4. Genes Dev 2015; 29:489-94. PubMed
  • Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res 2015; 75:628-34. PubMed
  • Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MI, O'Connor KW, Konstantinopoulos PA, Elledge SJ, Boulton SJ, Yusufzai T, D'Andrea AD. Homologous-recombination-deficient tumours are dependent on Polæ…®-mediated repair. Nature 2015; 518:258-62. PubMed
  • Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol Oncol 2014. PubMed
  • Shah MM, Dobbin ZC, Nowsheen S, Wieglos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN. An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. Gynecol Oncol 2014. PubMed
  • Choi YE, Battelli C, Watson J, Liu J, Curtis J, Morse AN, Matulonis UA, Chowdhury D, Konstantinopoulos PA. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. 2014; 5:2678-87. PubMed
  • Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: Current status and future promise. Gynecol Oncol 2014; 133:362-369. PubMed
  • Hecht JL, Konstantinopoulos PA, Awtrey CS, Soslow RA. Immunohistochemical Loss of BRCA1 Protein in Uterine Serous Carcinoma. Int J Gynecol Pathol 2014; 33:282-7. PubMed
  • Aird KM, Li H, Xin F, Konstantinopoulos PA, Zhang R. Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer. Cell Cycle 2014; 13:199-207. PubMed
  • Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol 2013; 31:4400-6. PubMed
  • Pedersen BS, Konstantinopoulos PA, Spillman MA, De S. Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients. Genes Chromosomes Cancer 2013; 52:794-801. PubMed
  • Battelli C, Campo M, Buss MK, Awtrey CS, Konstantinopoulos PA. Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube cancer. Chemotherapy 2014; 59:251-9. PubMed
  • Konstantinopoulos PA, Matulonis UA. Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer. 2013; 3:296. PubMed
  • Fountzilas E, Kelly AD, Perez-Atayde AR, Goldsmith J, Konstantinopoulos PA, Francoeur N, Correll M, Rubio R, Hu L, Gebhardt MC, Quackenbush J, Spentzos D. A microRNA activity map of human mesenchymal tumors: connections to oncogenic pathways; an integrative transcriptomic study. BMC Genomics 2012; 13:332. PubMed
  • Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, Hecht JL, Cannistra SA. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 2011. PubMed
  • Konstantinopoulos PA, Cannistra SA, Fountzilas H, Culhane A, Pillay K, Rueda B, Cramer D, Seiden M, Birrer M, Coukos G, Zhang L, Quackenbush J, Spentzos D. Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PLoS ONE 2011; 6:e18202. PubMed
  • Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010; 28:3555-61. PubMed
  • Zachos I, Konstantinopoulos PA, Tzortzis V, Gravas S, Karatzas A, Karamouzis MV, Melekos M, Papavassiliou AG. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Expert Opin Investig Drugs 2010; 19:875-87. PubMed
  • Konstantinopoulos PA, Fountzilas E, Goldsmith JD, Bhasin M, Pillay K, Francoeur N, Libermann TA, Gebhardt MC, Spentzos D. Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance. PLoS ONE 2010; 5:e9747. PubMed
  • Zachos I,Konstantinopoulos PA,Vandoros GP,Karamouzis MV,Papatsoris AG,Podimatas T,Papachristodoulou A,Chrisofos M,Deliveliotis C,Papavassiliou AG. Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy. J Cancer Res Clin Oncol 2009; 135:1169-75. PubMed
  • Kassimatis TI, Konstantinopoulos PA. Rosuvastatin in patients undergoing hemodialysis. N Engl J Med 2009; 361:93; author reply 94-5. PubMed
  • Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol 2009; 10:709-17. PubMed
  • Burga LN,Tung NM,Troyan SL,Bostina M,Konstantinopoulos PA,Fountzilas H,Spentzos D,Miron A,Yassin YA,Lee BT,Wulf GM. Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer Res 2009; 69:1273-8. PubMed
  • Konstantinopoulos PA, Spentzos D, Cannistra SA. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 2008; 5:577-87. PubMed
  • Konstantinopoulos PA, Goldsztein H, Dezube BJ, Pantanowitz L. Acquired immunodeficiency syndrome related Kaposi's sarcoma eroding the maxillary bone. J Laryngol Otol 2007; 122:993-7. PubMed
  • Konstantinopoulos PA,Fountzilas E,Pillay K,Zerbini LF,Libermann TA,Cannistra SA,Spentzos D. Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med Genomics 2008; 1:59. PubMed
  • Konstantinopoulos PA, Dezube BJ, Pantanowitz L, Horowitz GL, Beckwith BA. Protein electrophoresis and immunoglobulin analysis in HIV-infected patients. Am J Clin Pathol 2007; 128:596-603. PubMed
  • Konstantinopoulos PA, Sullivan RJ, Karamouzis MV, Dezube BJ. Investigational agents for treatment of AIDS-related Kaposi's sarcoma. Expert Opin Investig Drugs 2007; 16:495-504. PubMed
  • Konstantinopoulos PA, Dezube BJ, March D, Pantanowitz L. HIV-associated intramammary lymphadenopathy. Breast J 2007; 13:192-5. PubMed
  • Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, Di Trolio R, De Placido S, Dezube BJ. Management of AIDS-related Kaposi's sarcoma. Lancet Oncol 2007; 8:167-76. PubMed
  • Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, Friedman T, Konstantinopoulos PA, Spentzos D, Ghebremichael M, Stevenson K, Neuberg D, Levine JD, Joyce R, Tzachanis D, Boussiotis V, Kufe D, Avigan D. Generation of Tumor-specific T Lymphocytes Using Dendritic Cell/Tumor Fusions and Anti-CD3/CD28. J Immunother 2010; 33:155-66. PubMed
Hide